Exhibit
99.1
| Company: |
Media/Investors: |
| Robert Farrell |
Jonathan Fassberg |
| Executive Vice President &
CFO |
The Trout Group |
| 650-244-4990 |
212-477-9077 |
FOR
IMMEDIATE RELEASE
TITAN
PHARMACEUTICALS APPOINTS DR. JOACHIM-FRIEDRICH KAPP TO ITS BOARD OF
DIRECTORS
South
San Francisco, CA - September 1, 2005 - Titan
Pharmaceuticals, Inc. (AMEX: TTP) today announced that Dr. Joachim-Friedrich
Kapp has been appointed to the Company’s Board of Directors. Dr. Kapp is
currently President, Global Business Unit Specialized Therapeutics, at Schering
AG, Germany. Schering AG is Titan’s corporate partner for the development of
Spheramine®.
“We
are
delighted to add Dr. Kapp to our Board of Directors,” stated Dr. Louis R.
Bucalo, Chairman, President and CEO of Titan. “We believe that Dr. Kapp’s
expertise and experience in pharmaceutical development will be a valuable
additional asset to Titan.”
From
1975-1983, Dr. Kapp held positions of increasing responsibility at both Schering
AG and its U.S. subsidiary Berlex, eventually being named in 1983 as Head of
Schering AG’s Cardiovascular Segment Management. In 1984, Dr. Kapp joined
Gödecke AG, a subsidiary of Warner-Lambert, where he ultimately became Head of
Research and Development, as well as Vice President and Head, International
Clinical Development for Warner-Lambert. In 1991, Dr. Kapp returned to Schering
AG where he thereafter was appointed President, GBU Specialized Therapeutics.
Concurrent
with Dr. Kapp’s appointment to the Board, Dr. Ernst Afting will be retiring from
Titan’s Board of Directors. Dr. Afting will continue to work with Titan as a
consultant to the company.
“I
am
very pleased to join Titan’s Board of Directors,” said Dr. Kapp. “Titan is an
innovative Company with several products in clinical testing. I look forward
to
working with the Company as it advances its development programs.”
About
Titan Pharmaceuticals
Titan
Pharmaceuticals, Inc. (AMEX: TTP) is a biopharmaceutical company focused on
the
development and commercialization of novel treatments for central nervous system
disorders, cardiovascular disease, bone disease and other disorders. Titan's
products in development utilize novel technologies that have the potential
to
significantly improve the treatment of these diseases. Titan also establishes
partnerships with government institutions and other leading pharmaceutical
development companies. For more information, please visit the Company’s website
at www.titanpharm.com
The
press
release may contain "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act
of 1934. Such statements include, but are not limited to, any statements
relating to the Company's development program and any other statements that
are
not historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to
difficulties or delays in development, testing, regulatory approval, production
and marketing of the Company's drug candidates, unexpected adverse side effects
or inadequate therapeutic efficacy of the Company's drug candidates that could
slow or prevent product development or commercialization, the uncertainty of
patent protection for the Company's intellectual property or trade secrets
and
the Company's ability to obtain additional financing if necessary. Such
statements are based on management's current expectations, but actual results
may differ materially due to various factors, including those risks and
uncertainties mentioned or referred to in this press release.
#
#
#
